Полный список литературы

Предупреждение! Препарат рецептурного отпуска! Использовать только после назначения врача!
Xefocam® Монография
  1. Orfanos, S. E., Mavrommati, I., Korovesi, I., and Roussos, C. Pulmonary endothelium in acute lung injury: from basic science to the critically ill. Intensive Care Med. 30(9), 1702-1714. 2004.
  2. Topol, E. J. Failing the public health--rofecoxib, Merck, and the FDA - Correspondance. N.Engl.J.Med. 351(27), 2877. 21-10-2005.
  3. Fitzgerald, G. A. Coxibs and cardiovascular disease. N.Engl.J.Med. 351(17), 1709-1711. 21-10-2004.
  4. McCormack, K. and Brune, K. Dissociation between the Antinociceptive and Anti-Inflammatory Effects of the Nonsteroidal Anti-Inflammatory Drugs. A Survey of their Analgesic Efficacy. Drugs 41(4), 533-547. 1991.
  5. McCormack, K. and Urquhart, E. Correlation between Nonsteroidal Anti-Inflammatory Drug Efficacy in a Clinical Pain Model and the Dissociation of their Anti-Inflammatory and Analgesic Properties in Animal Models. Clinical Drug Investigation 9(2), 88-97. 1995.
  6. Atzpodien, E., Mehdi, N., Clarke, D., and Radhofer-Welte, S. Subacute and chronic oral toxicity of lornoxicam in cynomolgus monkeys. Food Chem.Toxicol. 35(5), 465-474. 1997.
  7. El Dareer, S. M., Noker, P. E., and Galbraith, W. M. Disposition of [14C] lornoxicam in male and female cynomolgus monkeys dosed orally or intravenously. The FASEB Journal 4(3), A461 (Abstr. 1132). 1990.
  8. Fukuzaki, K., Koja, T., Kamenosono, T., Nagatomo, M., Nagata, R., Tanaka, M., and Higuchi, S. General pharmacological studies of Lornoxicam. Japanese Pharmacology and Therapeutics 25(2), 81-101. 1997.
  9. Jolliet, P., Bree, F., Urien, S., Albengres, E., and Tillement, J. P. Blood to brain transfer of various oxicams: Comparison of the effects of plasma binding on their delivery to the brain. Conference de Biologie Cerebro-Vasculaire (Abstract). 1995.
  10. Pohlmeyer-Esch, G., Mehdi, N., Clarke, D., and Radhofer-Welte, S. Evaluation of chronic oral toxicity and carcinogenic potential of lornoxicam in rats. Food Chem.Toxicol. 35(9), 909-922. 1997.
  11. Pruss, T. P., Stroissnig, H., Radhofer-Welte, S., Wendtlandt, W., Mehdi, N., Takacs, F., and Fellier, H. Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgraduate Medical Journal 66(Suppl.4), S18-S21. 1990.
  12. Urano, H., Shinohara, K., Yamaguchi, J., Itomasa, H., and Suwa, T. Metabolic fate of TS-110, a new anti-inflammatory agent (1). Metabolism in rats. 112th Annual Meeting of the Pharmaceutical Society of Japan, Fukuoka, Abstract 31 KA 10-82. 1992.
  13. Pruss, T. P., Stroissnig, H., and Ferber, H. P. Lornoxicam, a novel highly potent anti-inflammatory and analgesic agent which does not penetrate the brain. 3rd Interscience world conference on inflammation, antirheumatics, analgesics immunmodulators,Monte Carlo, 41. 1989.
  14. McCormack, K. The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects. Drugs 47 Suppl 5, 28-45. 1994.
  15. Berg, J., Christoph, T., and Bodenteich, A. Isoenzyme-specific cyclooxygenase inhibitors: a whole cell assay system uring the human erythroleukemic cell line HEL and the human monocytic cell line Mono Mac 6. Journal of Pharmacological and Toxicological Methods 37(4), 179-186. 1997.
  16. Futaki, N., Takahashi, S., Kitagawa, T., Yamakawa, Y., Tanaka, M., and Higuchi, S. Anti-inflammatory, analgesic, antipyretic and cyclooxygenase inhibitory effects of a non-steroidal anti-inflammatory agent, Lornoxicam. Japanese Pharmacology and Therapeutics 25(4), 55-71. 1997.
  17. Balfour, J. A., Fitton, A., and Barradell, L. B. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 51(4), 639-657. 1996.
  18. Kullich, W. and Klein, G. Influence of the nonsteroidal antiinflammatory drug lornoxicam i.v. on the secretion of the endogenous opiate peptides dynorphin and beta-endorphin. Aktuelle Rheumatologie 17, No.4, 128-132. 1992.
  19. Stimmeder, D. Antinociceptive effects of lornoxicam in the PBQ writhing test in mice, iv vs icv administration. Data on File. 1992. Nycomed.
  20. Buritova, J. and Besson, J. M. Dose-related anti-inflammatory/analgesic effects of lornoxicam: a spinal c-Fos protein study in the rat. Inflamm.Res. 47(1), 18-25. 1998.
  21. Bianchi, M. and Panerai, A. E. Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol.Res. 45(2), 101-105. 2002.
  22. Abramson, S. B. and Weissmann, G. The mechanisms of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 32(1), 1-9. 1989.
  23. Cashin, C. H. and Meen, N. D. Antipyretic activity of anti-inflammatory drugs in rats: results of testing indomethacin, carprofen, diclofenac, piroxicam and paracetamol in comparison with Ro 13-9297, Ro 14-0046 and Ro 14-1419. Roche Internal Research Report No. 178. Data on File. 1980. Nycomed.
  24. Dittrich, P. Bioavailability of Lornoxicam after 8 mg i. v., 8 mg i. m., 8 mg as suppository, 8 mg p. o., 16 mg p. o. (CT 64). Data on File. 18-5-1993. Nycomed.
  25. Skjodt, N. M. and Davies, N. M. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin.Pharmacokinet. 34(6), 421-428. 1998.
  26. Nahler, G. The pharmacokinetics of C-14-Chlortenoxicam (= Lornoxicam) applied as oral solution (CT 38 and CT 38A). Data on File. 28-4-1993. Nycomed.
  27. Hitzenberger, G., Radhofer-Welte, S., Takacs, F., and Rosenow, D. Pharmacokinetics of lornoxicam in man. Postgraduate Medical Journal 66, Suppl.4, S22-S26. 1990.
  28. Ankier, S. I., Brimelow, A. E., Crome, P., Johnston, A., Warrington, S. J., Turner, P., and Ferber, H. P. Chlortenoxicam pharmacokinetics in young and elderly human volunteers. Postgraduate Medical Journal 64, 752-754. 1988.
  29. Strobel, W. Phase I, Single Centre Study to Evaluate the Pharmacokinetics of Lornoxicam in 24 (12 Elderly and 12 Young) Healthy Volunteers After Single and Multiple Dose Conditions (CT 81). Data on File. 28-4-1995. Nycomed.
  30. Mayerhofer, S., Welte, S., Magometschnigg, D., and Ferber, H. P. The effect of food on pharmacokinetic parameters of the new НПВП lornoxicam in healthy volunteers. 3rd interscience world conference on inflammation, antirheumatics, analgesics,immunmodulators,Monte Carlo, 223. 1989.
  31. Dittrich, P., Radhofer-Welte, S., Mayerhofer, S., Kukovetz, W. R., and Ferber, H. P. Comparative pharmacokinetics of parenteral lornoxicam. Eur.J.Pharmacol. 183, 2265-2266. 1990.
  32. Dittrich, P., Radhofer-Welte, S., Magometschnigg, D., Kukovetz, W. R., Mayerhofer, S., and Ferber, H. P. The effect of concomitantly administered antacids on the bioavailabiblity of lornoxicam, a novel highly potent НПВП. Drugs Exp.Clin.Res. 16 (2), 57-62. 1990.
  33. Radhofer-Welte, S., Dittrich, P., Danneskiold-Samsøe, P., and Møller, P. L. The pharmacokinetics of lornoxicam as quick release tablet, standard tablet and intramuscular injection. Not Available. 2005.
  34. Geisler, J. Study for Evaluation of the Pharmacokinetics after Multiple Dose Administration of Lornoxicam 8 mg Tablets in Patients with Impaired Liver Function Compared to Healthy Controls (CT 73). Data on File. 21-7-1993. Nycomed.
  35. Albengres, E., Urien, S., Barre, J., Nguyen, P., Bree, F., Jolliet, P., Tillement, J. P., Tsai, R. S., Carrupt, P. A., and Testa, B. Clinical pharmacology of oxicams: New insights into the mechanisms of their dose-dependent toxicity. International Journal of Tissue Reaction 15(3), 125-134. 1993.
  36. Olkkola, K. T., Brunetto, A. V., and Mattila, M. J. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin. Pharmacokinetics 26(2), 107-120. 1994.
  37. Radhofer-Welte, S. and Dittrich, P. Determination of the novel non-steroidal anti-inflammatory drug lornoxicam and its main metabolite in plasma and synovial fluid. J. Chromatogr. B Biomed. Sci. Appl. 707(1-2), 151-159. 10-4-1998.
  38. Kohl, Ch., Kocian, M., Paschinger, D., and Radhofer, S. Interactions of potent tolbutamide 4-hydroxylase inhibitors with the metabolism of Lornoxicam in human liver microsomes. ISSX Procceedings 11, 166. 1997.
  39. Unseld, E., Radhofer-Welte, S., Molz, K.-H., Haug-Pihale, G., Grune, D., and Frenzel, W. Disposition of lornoxicam and its 5'-hydroxy-metabolite in relation to the sparteine and mephenytoin oxidation polymorphism. European Journal of Drug Metabolism and Pharmacokinetics- Proc. Europ. Congr. Biopharm. Pharmacok., Brussels, 87-93. 1994.
  40. Bonnabry, P., Dayer, P., and Leemann, T. Role of human liver cytochrome P450TB (CYP2C9) in the biotransformation of Lornoxicam. Clin. Pharmacology and Therapeutics 57(2 - Abstract PI-70), 152. 1995.
  41. Bonnabry, P., Leemann, T., and Dayer, P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur.J.Clin.Pharmacol. 49(4), 305-308.1996.
  42. Kohl, C. and Steinkellner, M. Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos. 28(2), 161-168. 2000.
  43. Iida, I., Miyata, A., Arai, M., Hirota, M., Akimoto, M., Higuchi, S., Kobayashi, K., and Chiba, K. Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation. Drug Metab Dispos. 32(1), 7-9. 2004.
  44. Zhang, Y., Zhong, D., Si, D., Guo, Y., Chen, X., and Zhou, H. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br. J. Clin. Pharmacol. 59(1), 14-17. 2005.
  45. Anthony, M. and Berg, M. J. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I. J Women's Health Gend .Based. Med. 11(7), 601-615. 2002.
  46. Miners, J. O. and Birkett, D. J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J Clin Pharmacol. 45(6), 525-538. 1998.
  47. Ravic, M., Salas-Herrera, I., Johnston, A., Turner, P., Foley, K., and Rosenow, D. Influence of lornoxicam a new non-steroidal antiinflammatory drug on lithium pharmacokinetics. Human Psychopharmacology 8, 289-292. 1993.
  48. Ravic, M., Salas-Herrera, I., Johnston, A., Turner, P., Foley, K., and Rosenow, D. E. A pharmacokinetic interaction between cimetidine or ranitidine and lornoxicam. Postgrad. Med. J. 69(817), 865-866. 1993.
  49. Nahler, G. An open study to determine the effect of renal insufficiency on the pharmacokinetics of Lornoxicam and to assess the tolerability of the drug in patients with renal insufficiency (CT 74). Data on File. 19-8-1993. Nycomed.
  50. Radhofer-Welte, S. Pharmacokinetics and tolerability of Lornoxicam film-coated tablets on patients suffering from mild, moderate and severe renal impairment. Data on File. 13-5-1993. Nycomed.
  51. Warrington, S. J. and et al. Chlortenoxicam and renal function of normal human volunteers. Letter to the editor. Human Toxicology 8(1), 53-54. 1989.
  52. Ehrenkrook, D. V. and Glocker, B. Evaluation of potential pharmacokinetic interaction between Aspirin and Chlortenoxicam (Lornoxicam) in healthy men (CT 47). Data on File. 7-6-1993. Nycomed.
  53. Ravic, M., Johnston, A., Turner, P., Foley, K., and Rosenow, D. Doses bismuth chelate influence lornoxicam absorption? (Letters to the editor). Human & Experimental Toxicology 11, 59-61. 1992.
  54. Welte, S., Ferber, H. P., and Binder, D. A single dose pharmacokinetic and tolerance study of a new non steroidal anti-inflammation drug CLTX. III World Conference on Clinical Pharmacology & Therapeutics, Stockholm , 55, Abstract 89. 1986.
  55. Walden, R. J., Owens, C. W. I., Graham, B. R., Snape, A., Nutt, J., and Prichard, B. N. C. НПВПs and the control of hypertension: a pilot study. British Journal of Clinical Phamracology 33(2), 241P. 1992.
  56. Hitoglou-Makedou, A., Lawson, M., Turner, P., and Ferber, H. P. Comparison of chlortenoxicam and indomethacin on frusemide-induced diuresis. Postgraduate Medical Journal 65, 821-823. 1989.
  57. Ravic, M., Johnston, A., and Turner, P. Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs. Postgraduate Medical Journal 66(Suppl.4), S30-S34. 1990.
  58. N.N. Study of Possible Pharmacokinetic Interaction between Chlortenoxicam and Methotrexate in Patients with Chronic Arthritis. Data on File. 8-7-1993. Nycomed.
  59. Masche, U. P., Rentsch, K. M., von Felten, A., Meier, P. J., and Fattinger, K. E. Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics. Eur. J. Clin. Pharmacol. 54(11), 857-864. 1999.
  60. Masche, U. P., Rentsch, K. M., von Felten, A., Meier, P. J., and Fattinger, K. E. No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics. Eur. J. Clin. Pharmacol. 54(11), 865-868. 1999.
  61. Ravic, M., Johnston, A., Turner, P., and Ferber, H. P. A study of the interaction between lornoxicam and warfarin in healthy volunteers. Human & Experimental Toxicology 9, 413-414. 1990.
  62. CPMP/EWP. Note of Guidance for the Clinical Evaluation of Medicinal Products for Treatment of Nociceptive Pain. CPMP/EWP/612/00. 21-11-2002. EMEA.
  63. McCormack, K. The evolving НПВП: focus on lornoxicam. Pain Reviews 6(4), 262-278. 1999.
  64. Moote, C. Efficacy of Nonsteroidal Anti-Inflammatory Drugs in the management of Postoperative Pain. Drugs 44(Suppl. 5), 14-30. 1992.
  65. Fuglerud, P. Three meta-analyses of lornoxicam pain studies. Data on File. 14-2-1995.
  66. Norholt, S. E., Sindet-Pedersen, S., Larsen, U., Bang, U., Ingerslev, J., Nielsen, O., Hansen, H. J., and Ersboll, A. K. Pain control after dental surgery: a double-blind, randomised trial of lornoxicam versus morphine. Pain 67(2-3), 335-343. 1996.
  67. Laska, E., Siegel, C., and Sunshine, A. Onset and duration: Measurement and analysis. Clin. Pharm. Ther. 49(1), 1-5. 1991.
  68. Forbes, A. Oral Surgery. Max, M. B., Portenoy, R. K., and Laska, E. M. The Design of Analgesic Clinical Trials. (15), 347-374. 1991. New York, Raven Press. Advances in Pain Research and Therapy.
  69. Norholt, S. E., Sindet-Pedersen, S., Bugge, C., Branebjerg, P. E., Ersboll, B. K., and Bastian, H. L. A randomized, double-blind, placebo-controlled, dose-response study of the analgesic effect of lornoxicam after surgical removal of mandibular third molars. J. Clin. Pharmacol. 35(6), 606-614. 1995.
  70. Patel, A., Skelly, A. M., Kohn, H., and Preiskel , H. W. Double-blind placebo-controlled comparison of the analgesic effects of single doses of lornoxicam and aspirin in patients with post-operative dental pain. British Dental Journal 170(8), 295-299. 1991.
  71. Desjardins, P. J., Norris, L., Doku, H. C., Papageorge, M., and Chase, J. Analgesic efficacy of lornoxicam in dental impaction pain. Clinical Pharmacology & Therapeutics 51(2), 123 (Abstr. PI-7). 1992.
  72. Cooper, S. A., Fielding, A. F., Lucyk, D., Hersh, E. V., Quinn, P. D., Betts, N., Abaza, N., and Smith, B. Lornoxicam: Analgesic efficacy and safety of a new oxicam derivative. Advances in Therapy 13(1), 67-77. 1996.
  73. Møller, P. L. and Norholt, S. E. Analgesic efficacy of lornoxicam as quick release tablet versus standard tablet in postoperative pain: a randomised, placebo-controlled trial in the dental pain model. Not Available . 2005.
  74. Ilias, W. and Jansen, M. Pain control after hysterectomy: an observer-blind, randomised trial of lornoxicam versus tramadol. Br. J. Clin. Pract. 50(4), 197-202. 1996.
  75. Bugge, C. A double-blind, placebo controlled comparison of Chlortenoxicam with Aspirin in patients suffering from postpartum episiotomy pain, CT02. Data on File. 1-7-1993. Nycomed.
  76. Trampitsch, E., Pipam, W., Moertl, M., Sadjak, A., Dorn, C., Sittl, R., and Likar, R. [Preemptive randomized, double-blind study with lornoxicam in gynecological surgery]. Schmerz. 17(1), 4-10. 2003.
  77. Rosenow, D. E., Albrechtsen, M., and Stolke, D. A comparison of patient-controlled analgesia with lornoxicam versus morphine in patients undergoing lumbar disk surgery. Anesth. Analg. 86(5), 1045-1050. 1998.
  78. Staunstrup, H., Ovesen, J., Larsen, U. T., Elbaek, K., Larsen, U., and Kroner, K. Efficacy and tolerability of lornoxicam versus tramadol in postoperative pain. J. Clin. Pharmacol. 39(8), 834-841. 1999.
  79. Rosenow, D. E., Van Krieken, F., and Kursten, F. W. Intravenous administration of Lornoxicam, a new НПВП, and Pethidine for postoperative pain. A placebo-controlled pilot study. Clinical Drug Investigation 11(1), 11-19. 1996.
  80. Kremastinou, R., Xistra, A., Leventis, A., Papastamou, M., Papvasilopoulou, T., and Economou, A. Combination of morphine and Lornoxicam via PCA pump in transvesical prostatectomies. Recent Views on Clinical Pain . 2002.
  81. Balanika, M., Tsitsika, M., and Wilczynski, W. The use of lornoxicam-meperidine combination for postoperative analgesia. European Journal of Anaesthesiology 17, 771. 2000.
  82. Nikoda, V. V., Maiachkin, R. B., Bondarenko, A. V., Mikhailov, IuE, and Anosova, N. P. [Use of lornoxicam for analgesia in the early postoperative period]. Anesteziol.Reanimatol. (6), 47-50. 2001.
  83. Papaioannou, E. and et al. Comparison of preoperative i.m. Lornoxicam, diclofenac and paracetamol in postoperative pain management after tonsillectomy. Recent Views on Clinical Pain . 2002.
  84. Tsitsika, M., Balanika, M., Paparrizou, N., Tsoga, S., and Plessia, H. Preemptive analgesia with lornoxicam in laparoscopic cholecystectomies. ESA Congress Abstract . 2001.
  85. Agianniotaki, E. and et al. Assessment of direct postoperative pain in patients undergoing laparoscopic cholecystectomy. Comparison of lornoxicam and ketoprofen i.m. administration. The International Monitor 12(3), 242. 2000.
  86. Harreby, M., Kjer, J., Hesselsoe, G., and Neergaard, K. Epidemiological aspects and risk factors for low back pain in 38-year-old men and women: a 25-year prospective cohort study of 640 school children. Eur. Spine J. 5(5), 312-318. 1996.
  87. Hillman, M., Wright, A., Rajaratnam, G., Tennant, A., and Chamberlain, M. A. Prevalence of low back pain in the community: implications for service provision in Bradford, UK. J. Epidemiol. Community Health 50(3), 347-352. 1996.
  88. Leboeuf-Yde, C., Klougart, N., and Lauritzen, T. How common is low back pain in the Nordic population? Data from a recent study on a middle-aged general Danish population and four surveys previously conducted in the Nordic countries. Spine 21(13), 1518-1525. 1-7-1996.
  89. Zonjee, M., Nienhuis, H., and Pieterse, H. A placebo-controlled, single-blind study of the analgesic efficacy and safety of lornoxicam as a single intramuscular injection or a single oral dose in patients with acute sciatica/lumbosciatica [study CT 85]. Data on File. 1995.
  90. Rainer, F., Klein, G., Mayrhofer, F., Singer, F., Uray, H., and Kursten, F. W. A prospective, multicentre,open-label,uncontrolled Phase II study of the local tolerability, safety and efficacy of intramuscular chlortenoxicam in patients with acute low back pain. European Journal of Clinical Research 8, 1-13. 1996.
  91. Branebjerg, P. E. Lornoxicam in Cancer Pain: A multi-study evaluation of the analgesic efficacy of Lornoxicam in cancer patients. Data on File. 7-7-1995. Nycomed.
  92. Branebjerg, P. E. A multicentre, randomised, double-blind, parallel group design study comparing the therapeutic efficacy and safety of Lornoxicam and Naproxen in patients suffering from acute low-back pain. Data on File. 30-6-1993.
  93. Møller, P. L. A randomised, double-blind, multi-centre, clinical trial comparing Efficacy and Safety of the oral quick release formulation of Lornoxicam with Diclofenac Potassium in patients suffering from acute low back pain. Data on File. 14-3-2005.
  94. Mayrhofer, F., Siegmeth, W., Kolarz, G., Singer, F., Klein, G., Scherak, O., and Kursten, F. W. A multicentre,randomised,double-blind study comparing Lornoxicam with conventional diclofenac in patients with chronic low back pain. Annals of Experimental and Clinical Medicine 1(5-6), 283-290. 1994.
  95. Bias, P. and Kursten, F. W. Analgesic therapy in chronic low back pain: comparative study of lornoxicam versus placebo and naproxen. Der Schmerz 8(Suppl.1), S50,Abstract P70. 1994.
  96. Bugge, C. A randomised, parallel group trial with chlortenoxicam and naproxen in patients with pain due to bone tumours [study CT 17]. Data on File. 1993. Nycomed.
  97. Krimmer, J. A prospective, double-blind, place controlled, dose range finding study wioth lornoxicam in active rheumatoid arthritis (RA) patients (anatomical stage II) using a fixed dosage regime in parallel treatment groups with 4 days wash-out and an active medication phase of 3 week (CT 60). Data on File. 6-2-1995. Nycomed.
  98. Krimmer, J. A multicentre, randomized, double-blind, parallel group design study comparing the effects of multiple doses of lornoxicam versus piroxicam in patients with rheumatoid arthritis during a three month period followed by a continuation of treatment in an open design in those patients receiving lornoxicam for a period of ten months (ct 28). Data on File. 22-3-1993. Nycomed.
  99. N.N. Hafslund Nycomed's R&D in 1992. DN&P 6(2). 1993.
  100. Braun, M. A multicentre, open study of the safety and tolerance of lornoxicam, freely titrated, in patients with rheumatoid arthritis or osteoarthritis who have completed a previous study of the drug and elected to continue the treatment (CT 77). Data on File. 15-3-1996. Nycomed.
  101. Krimmer, J. A multicentre, prospective, double-blind, randomized, parallel group designed study with Lornoxicam versus Diclofenac in active rheumatoid arthritis (RA) patients during an eight weeks period followed by Lornoxicam treatment in all patients for a period of forty-four weeks (3n = 180) (CT 61). Data on File. 2-9-1993. Nycomed.
  102. Caruso, I., Montrone, F., Boari, L., Davoli, C., Beyene, N. B., Caporali, R., and et al. Lornoxicam versus diclofenac in rheumatoid arthritis: a double-blind, multicenter study. Advances in Therapy 11(3), 132-138. 1994.
  103. Bernstein, R. M. and Frenzel, W. A comparative study of 2 dosage regimens of Lornoxicam and a standard dosage of naproxen in patients with rheumatoid arthritis. European Journal of Clinical Research 7, 259-273. 1995.
  104. Tsurko, V. V., Parnes, E. I., and Krasnosel'skii, M. I. [Clinical efficacy of xefocam and its effect on arterial pressure and heart rhythm variability in patients with rheumatoid arthritis in combination with arterial hypertension]. Ter.Arkh. 74(5), 63-66. 2002.
  105. Berry, H., Bird, H. A., Black, C., Blake, D. R., Freeman, A. M., Golding, D. N., Hamilton, E. B. D., Jayson, M. I. V., Kidd, B., Kohn, H., Million, R., Ollier, S., Smith, I., Williams, B. D., and Woolf, A. D. A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee. Annals of the Rheumatic Diseases 51, 238-242. 1992.
  106. Kidd, B. and Frenzel, W. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J.Rheumatol. 23(9), 1605-1611. 1996.
  107. Whittington, J. R. A multicentre, randomised, double-blind, parallel group design comparing the effects of multiple doses of Lornoxicam (Chlortenoxicam) versus Naproxen in patients with osteoarthritis during a three month period followed by a continuation of treatment in an open design in those patients receiving Lornoxicam for a period of six months [later extended to 9 months] (CT 33). Data on File. 30-6-1993. Nycomed.
  108. Krimmer, J. A randomised, double-blind, cross-over comparison of Chlortenoxicam, Naproxen, and Placebo in patients with Osteoarthritis (CT 45). Data on File. 23-3-1993. Nycomed.
  109. Rose, P. and Steinhauser, C. Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis. Clin Drug Invest 24(4), 227-236. 21-5-2004. Addis.
  110. Marty, M. Study of long-term clinical tolerance and effects on laboratory parameters of Lornoxicam in elderly subjects suffering from osteoarthritis of the lower limbs or rheumatoid arthritis (CT 62). Data on File. 22-6-1993. Nycomed.
  111. Bernstein, R. M., Calin, H. J., Calin, A., and Ollier, S. A comparison of the efficacy and tolerability of lornoxicam and indomethacin in ankylosing spondylitis. European Journal of Rheumatology and Inflammation 12, No.3, 6-13. 1992.
  112. Kursten, F. W. and Bias, P. Lornoxicam: An alternative in treatment of pain? A prospective study in patients suffering from chronic low back pain. Der Schmerz 8(Suppl.1), S51,Abstr.P71. 1994.
  113. Krimmer, J. A multicentre, randomized, double-blind trial of Chlortenoxicam (Lornoxicam) in patients with rheumatoid arthritis (CT 05). Data on File. 16-4-1993. Nycomed.
  114. Krimmer, J. A multicentre, double-blind, parallel group, randomized trial of Chlortenoxicam (Lornoxicam) in patients with rheumatoid arthritis (CT 15). Data on File. 22-3-1993. Nycomed.
  115. Krimmer, J. A multicentre, double blind, randomized, parallel group, phase III, long-term study with Lornoxicam (8 mg b.i.d., 16 mg o.d.) in active rheumatoid arthritis (RA) patients with an active medication phase of 52 weeks (2n = 100); (CT 69). Data on File. 7-7-1994. Nycomed.
  116. Krimmer, J. A multicentre, randomized, double-blind, parallel group design study comparing the effects of multiple doses of Lornoxicam versus Diclofenac in patients with rheumatoid arthritis during a three month period followed by a continuation of treatment in an open design in those patients receiving Lornoxicam for a period of nine months (CT 39). Data on File. 16-8-1993. Nycomed.
  117. Bias, P. Eficacy and safety of two different dosages of Lornoxicam (4 mg bid and 8 mg bid) in comparison with placebo in patients with osteoarthrosis of the knee (CT80). Data on File. 1-9-1993. Nycomed.
  118. Bias, P. A multicenter, randomized, double blind trial of Chlortenoxicam in patients with Osteoarthritis (CT 04). Data on File. 2-4-1993. Nycomed.
  119. Hawkey, C. J. Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. Scand. J Gastroenterol. Suppl 220, 124-127. 1996.
  120. Fries, J. F., Williams, C. A., Bloch, D. A., and Michel, B. A. Nonsteroid Anti-Inflammatory Drug-Associated Gastropathy: Incidence and Risk Factor models. American Journal of Medicine 91, 213-222. 1991.
  121. McCormack, K. Roles of COX-1 and COX-2. Journal of Rheumatology 25(11), 2279-2281. 1998.
  122. McCormack, K. and Twycross, R. COX-2 Selective inhibitors and analgesia. Pain Clinical Updates 10(1), 1-4. 2002.
  123. Topol, E. J. Failing the public health - rofecoxib, Merck, and the FDA. N. Engl. J. Med. 351(17), 1707-1709. 21-10-2004.
  124. Henry, D., Page, J., Whyte, I, Nanra, R., and Hall, C. Consumption of Non-Steroidal Anti-Inflammatory Drugs and the Development of Functional Renal Impairment in Elderly Subjects - Results of a Case-Control Study. British Journal of Clinical Pharmacology 44(1), 85-90. 1997.
  125. Gabriel, S. E., Jaakkimainen, L., and Bambardier, C. Risk for serious gastrointestinal complications related to use of Nonsteroidal Anti-Inflammatory Drugs, A Meta-Analysis. Annals of Internal Medicine 115, 787-796. 1991.
  126. Phillips, A. C., Polisson, R. P., and Simon, L. S. НПВПs and the Elderly - Toxicity and Economic Implications [Review]. Drugs & Aging 10(2), 119-130. 1997.
  127. Griffin, M. R., Piper, J. M., Daugherty, J. R., Snowden, M., and Ray, W. A. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann. Intern. Med. 114(4), 257-263. 15-2-1991.
  128. Aabakken, L., Osnes, M., and Frenzel, W. Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers. Aliment. Pharmacol. Ther. 10(2), 151-156. 1996.
  129. Goggin, P. M., Collins, D. A., Jazrawi, R. P., Jackson, P. A., Corbishley, C. M., Bourke, B. E., and Northfield, T. C. Prevalence of helicobacter pylori infection and its effect on symptoms and non-steroidal anti-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis. Gut 34, 1677-1680. 1993.
  130. Meling, T. R., Aabakken, L., Roseth, A., and Osnes, M. Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand. J. Gastroenterol. 31(4), 339-344. 1996.
  131. Biscarini, L. Non-steroidal anti-inflammatory drugs. Dukes, M. N. G. Meyler's Side Effect of Drugs. 14th(9.2), 246-308. 2000. Elsevier.
  132. Walker, A. M. Quantitative Studies of the Risk of Serious Hepatic Injury in Persons using Nonsteroidal Antiinflammatory Drugs [Review]. Arthritis & Rheumatism 40(2), 201-208. 1997.
  133. Wen, S. F. Nephrotoxicities of Nonsteroidal Anti-Inflammatory Drugs [Review]. Journal of the Formosan Medical Association 96(3), 157-171. 1997.
  134. Bennett, W. M., Henrich, W. L., and Stoff, J. S. The Renal Effects of Nonsteroidal Anti-Inflammatory Drugs - Summary and Recommendations. American Journal of Kidney Diseases 28(Suppl 1), 56-62. 1996.
  135. Bückert, A. and Lücker, P. W. Second study with ascending single oral doses (20 - 160 mg) of Chlortenoxicam (= Ro 13 - 9297 = Lornoxicam) in healthy male volunteers (Lücker II). Data on File. 1985. Nycomed.
  136. Bückert, A. and Lücker, P. W. Ascending single oral dose tolerance study of Chlortenoxicam (= Ro 13 - 9297 = Lornoxicam) in healthy male volunteers (Lücker study I). Data on File. 7-5-1985. Nycomed.
  137. Turner, P. and Johnston, A. Clinical pharmacokinetic studies with lornoxicam. Postgraduate Medical Journal 66 (Suppl.4), S28-S29. 1990.
  138. Warrington, St. J., Debbas, N. M. G., Farthing, m., Horton, M., Johnston, A., Thillainayagam, A. V., Turner, P., and Ferber, H. Lornoxicam, indomethacin and placebo:comparison of effects on faecal blood loss and upper gastrointestinal endoscopic appearances in healthy men. Postgraduate Medical Journal 66, 622-626. 1990.
  139. Grarup, J., Olsen, K. J., Danneskiold-Samsøe, P., and Branebjerg, P. E. Clinical Safety Report. 1-71. 21-12-2001. Nycomed.
  140. Rodriguez, L. A. Nonsteroidal Antiinflammatory Drugs, Ulcers and Risk - A Collaborative Meta-Analysis [Review]. Seminars in Arthritis & Rheumatism 26(6:Suppl 1), 16-20. 1997.
  141. Hernandez-Diaz, S. and Rodriguez, L. A. G. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation - An overview of epidemiologic studies published in the 1990s [Review]. Archives of Internal Medicine 160(14), 2093-2099. 24-7-2000.
  142. Rawal, N., Krøner, K., Likar, R., Homdrum, E., and Jakobsen, K. Safety of lornoxicam in the treatment of postoperative pain: a post-marketing study of lornoxicam versus standard analgesic treatment in 3752 day case surgery patients. Not Available. 2003.
1 марта 2008 г.

МЕДИ РУ в: МЕДИ РУ на YouTube МЕДИ РУ в Twitter МЕДИ РУ на FaceBook МЕДИ РУ вКонтакте Рейтинг@Mail.ru Яндекс.Метрика